{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:25:46Z","timestamp":1790832346968,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Last advances in the treatment of pediatric tumors has led to an increase of survival rates of children affected by primitive neuroectodermal tumors, however, still a significant amount of the patients do not overcome the disease. In addition, the survivors might suffer from severe side effects caused by the current standard treatments. Oncolytic virotherapy has emerged in the last years as a promising alternative for the treatment of solid tumors. In this work, we study the anti-tumor effect mediated by the oncolytic adenovirus VCN-01 in CNS-PNET models. VCN-01 is able to infect and replicate in PNET cell cultures, leading to a cytotoxicity and immunogenic cell death. <jats:italic>In vivo<\/jats:italic>, VCN-01 increased significantly the median survival of mice and led to long-term survivors in two orthotopic models of PNETs. In summary, these results underscore the therapeutic effect of VCN-01 for rare pediatric cancers such as PNETs, and warrants further exploration on the use of this virus to treat them.<\/jats:p>","DOI":"10.1038\/s41598-019-51014-1","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T10:04:19Z","timestamp":1570442659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-7753","authenticated-orcid":false,"given":"Marc","family":"Garcia-Moure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiara","family":"Martinez-Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Gonzalez-Huarriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Marrod\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Cascallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4066-8203","authenticated-orcid":false,"given":"Ana","family":"Pati\u00f1o-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-7351","authenticated-orcid":false,"given":"Marta M.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,7]]},"reference":[{"key":"51014_CR1","doi-asserted-by":"publisher","first-page":"x1","DOI":"10.1093\/neuonc\/nou327","volume":"16","author":"QT Ostrom","year":"2015","unstructured":"Ostrom, Q. T. et al. Alex\u2019s Lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro. Oncol. 16, x1\u2013x35 (2015).","journal-title":"Neuro. Oncol."},{"key":"51014_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0717-7","volume":"20","author":"P Sin-Chan","year":"2018","unstructured":"Sin-Chan, P., Li, B. K., Ho, B., Fonseca, A. & Huang, A. Molecular Classification and Management of Rare Pediatric Embryonal Brain Tumors. Curr. Oncol. Rep. 20, 69 (2018).","journal-title":"Curr. Oncol. Rep."},{"key":"51014_CR3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803\u2013820 (2016).","journal-title":"Acta Neuropathol."},{"key":"51014_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis, D. N. et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 114, 97\u2013109 (2007).","journal-title":"Acta Neuropathol."},{"key":"51014_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/neuonc\/nos292","volume":"15","author":"C Friedrich","year":"2013","unstructured":"Friedrich, C. et al. Treatment of young children with CNS-primitive neuroectodermal tumors\/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro. Oncol. 15, 224\u2013234 (2013).","journal-title":"Neuro. Oncol."},{"key":"51014_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/pbc.25405","volume":"62","author":"RI Jakacki","year":"2015","unstructured":"Jakacki, R. I. et al. Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children\u2019s Oncology Group. Pediatr. Blood Cancer 62, 776\u2013783 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"51014_CR7","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/0008-5472.CAN-06-4260","volume":"67","author":"S Ganesh","year":"2007","unstructured":"Ganesh, S. et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 67, 4399\u2013407 (2007).","journal-title":"Cancer Res."},{"key":"51014_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/mt.2010.79","volume":"18","author":"S Guedan","year":"2010","unstructured":"Guedan, S. et al. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther. 18, 1275\u201383 (2010).","journal-title":"Mol. Ther."},{"key":"51014_CR9","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","volume":"21","author":"A Rodr\u00edguez-Garc\u00eda","year":"2015","unstructured":"Rodr\u00edguez-Garc\u00eda, A. et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin. Cancer Res. 21, 1406\u20131418 (2015).","journal-title":"Clin. Cancer Res."},{"key":"51014_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/gt.2011.106","volume":"19","author":"JJ Rojas","year":"2012","unstructured":"Rojas, J. J., Gimenez-Alejandre, M., Gil-Hoyos, R., Cascallo, M. & Alemany, R. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Ther. 19, 453\u2013457 (2012).","journal-title":"Gene Ther."},{"key":"51014_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/mt.2010.173","volume":"18","author":"JJ Rojas","year":"2010","unstructured":"Rojas, J. J. et al. Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses. Mol. Ther. 18, 1960\u20131971 (2010).","journal-title":"Mol. Ther."},{"key":"51014_CR12","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1158\/1078-0432.CCR-15-1899","volume":"22","author":"N Mart\u00ednez-V\u00e9lez","year":"2016","unstructured":"Mart\u00ednez-V\u00e9lez, N. et al. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. Clin. Cancer Res. 22, 2217\u20132225 (2016).","journal-title":"Clin. Cancer Res."},{"key":"51014_CR13","doi-asserted-by":"publisher","first-page":"e0147211","DOI":"10.1371\/journal.pone.0147211","volume":"11","author":"B Vera","year":"2016","unstructured":"Vera, B. et al. Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. PLoS One 11, e0147211 (2016).","journal-title":"PLoS One"},{"key":"51014_CR14","doi-asserted-by":"publisher","first-page":"eaat9321","DOI":"10.1126\/scitranslmed.aat9321","volume":"11","author":"G Pascual-Pasto","year":"2019","unstructured":"Pascual-Pasto, G. et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci. Transl. Med. 11, eaat9321 (2019).","journal-title":"Sci. Transl. Med."},{"key":"51014_CR15","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/sj.mt.6300239","volume":"15","author":"M Cascallo","year":"2007","unstructured":"Cascallo, M. et al. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol. Ther. 15, 1607\u201315 (2007).","journal-title":"Mol. Ther."},{"key":"51014_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55\u201363 (1983).","journal-title":"J. Immunol. Methods"},{"key":"51014_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3171\/jns.2000.92.2.0326","volume":"92","author":"S Lal","year":"2000","unstructured":"Lal, S. et al. An implantable guide-screw system for brain tumor studies in small animals. J. Neurosurg. 92, 326\u2013333 (2000).","journal-title":"J. Neurosurg."},{"key":"51014_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"51014_CR19","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson, J. M. et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science (80-). 275, 1320\u20131323 (1997).","journal-title":"Science (80-.)."},{"key":"51014_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.addr.2005.01.007","volume":"57","author":"CB Coyne","year":"2005","unstructured":"Coyne, C. B. & Bergelson, J. M. CAR: A virus receptor within the tight junction. Adv. Drug Deliv. Rev. 57, 869\u2013882 (2005).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"51014_CR21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/sj.bjc.6600932","volume":"88","author":"M Kim","year":"2003","unstructured":"Kim, M. et al. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br. J. Cancer 88, 1411\u20131416 (2003).","journal-title":"Br. J. Cancer"},{"key":"51014_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1349-7006.2004.tb03232.x","volume":"95","author":"Y Tango","year":"2004","unstructured":"Tango, Y. et al. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells. Cancer Sci. 95, 459\u2013463 (2004).","journal-title":"Cancer Sci."},{"key":"51014_CR23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1089\/hum.2009.038","volume":"20","author":"N Bayo-Puxan","year":"2009","unstructured":"Bayo-Puxan, N. et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum. Gene Ther. 20, 1214\u20131221 (2009).","journal-title":"Hum. Gene Ther."},{"key":"51014_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","volume":"73","author":"TJ Wickham","year":"1993","unstructured":"Wickham, T. J., Mathias, P., Cheresh, D. A. & Nemerow, G. R. Integrins \u03b1v\u03b23 and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment. Cell 73, 309\u2013319 (1993).","journal-title":"Cell"},{"key":"51014_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/0092-8674(79)90333-7","volume":"17","author":"AJ Berk","year":"1979","unstructured":"Berk, A. J., Lee, F., Harrison, T., Williams, J. & Sharp, P. A. Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. Cell 17, 935\u2013944 (1979).","journal-title":"Cell"},{"key":"51014_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.virol.2011.12.006","volume":"424","author":"H Zhao","year":"2012","unstructured":"Zhao, H., Dahl\u00f6, M., Isaksson, A., Syv\u00e4nen, A.-C. & Pettersson, U. The transcriptome of the adenovirus infected cell. Virology 424, 115\u2013128 (2012).","journal-title":"Virology"},{"key":"51014_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"51014_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cancergen.2012.03.002","volume":"205","author":"M Li","year":"2012","unstructured":"Li, M. et al. Multiple CDK\/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor. Cancer Genet. 205, 220\u2013231 (2012).","journal-title":"Cancer Genet."},{"key":"51014_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","volume":"164","author":"D Sturm","year":"2016","unstructured":"Sturm, D. et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164, 1060\u20131072 (2016).","journal-title":"Cell"},{"key":"51014_CR30","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691 (2014).","journal-title":"Oncoimmunology"},{"key":"51014_CR31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang, F. F. et al. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J. Clin. Oncol. 36, 1419\u20131427 (2018).","journal-title":"J. Clin. Oncol."},{"key":"51014_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10043-0","volume":"10","author":"N Mart\u00ednez-V\u00e9lez","year":"2019","unstructured":"Mart\u00ednez-V\u00e9lez, N. et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat. Commun. 10, 2235 (2019).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51014-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51014-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51014-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:29:10Z","timestamp":1671287350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51014-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51014"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51014-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,7]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Cascallo has ownership interests (including patents) in and reports receiving commercial research support from VCN Biosciences. R. Alemany is a consultant\/advisory board member for VCN Biosciences. No potential conflicts of interest were disclosed by the other authors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. VCN Biosciences provided support in the form of salaries or research support for authors MC and RA, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14368"}}